Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 1
2012 1
2013 7
2014 4
2015 10
2016 11
2017 18
2018 14
2019 17
2020 19
2021 10
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 28510709

95 results

Results by year

Filters applied: . Clear all
Page 1
Effects of Ticagrelor, Prasugrel, or Clopidogrel on Endothelial Function and Other Vascular Biomarkers: A Randomized Crossover Study.
Ariotti S, Ortega-Paz L, van Leeuwen M, Brugaletta S, Leonardi S, Akkerhuis KM, Rimoldi SF, Janssens G, Gianni U, van den Berge JC, Karagiannis A, Windecker S, Valgimigli M; HI-TECH Investigators. Ariotti S, et al. JACC Cardiovasc Interv. 2018 Aug 27;11(16):1576-1586. doi: 10.1016/j.jcin.2018.04.022. Epub 2018 May 24. JACC Cardiovasc Interv. 2018. PMID: 29805112 Free article. Clinical Trial.
Secondary prevention of acute coronary events with antiplatelet agents (SPACE-AA): One-year real-world effectiveness and safety cohort study in the French nationwide claims database.
Blin P, Dureau-Pournin C, Benichou J, Bonello L, Dallongeville J, Danchin N, Falissard B, Thomas-Delecourt F, Jové J, Lassalle R, Droz C, Moore N. Blin P, et al. Atherosclerosis. 2019 Feb;281:98-106. doi: 10.1016/j.atherosclerosis.2018.11.037. Epub 2018 Dec 7. Atherosclerosis. 2019. PMID: 30658197
Efficacy and Safety of Clopidogrel, Prasugrel and Ticagrelor in ACS Patients Treated with PCI: A Propensity Score Analysis of the RENAMI and BleeMACS Registries.
Peyracchia M, Saglietto A, Biolè C, Raposeiras-Roubin S, Abu-Assi E, Kinnaird T, Ariza-Solé A, Liebetrau C, Manzano-Fernández S, Boccuzzi G, Henriques JPS, Wilton SB, Velicki L, Xanthopoulou I, Correia L, Rognoni A, Fabrizio U, Nuñez-Gil I, Montabone A, Taha S, Fujii T, Durante A, Gili S, Magnani G, Autelli M, Grosso A, Kawaji T, Blanco PF, Garay A, Quadri G, Queija BC, Huczek Z, Paz RC, González-Juanatey JR, Fernández MC, Nie SP, D'Amico M, Pousa IM, Kawashiri MA, Gallo D, Morbiducci U, Dominguez-Rodriguez A, Lopez-Cuenca A, Cequier A, Alexopoulos D, Iñiguez-Romo A, Grossomarra W, Usmiani T, Rinaldi M, D'Ascenzo F. Peyracchia M, et al. Am J Cardiovasc Drugs. 2020 Jun;20(3):259-269. doi: 10.1007/s40256-019-00373-1. Am J Cardiovasc Drugs. 2020. PMID: 31586336 Free article.
Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial.
Gimbel M, Qaderdan K, Willemsen L, Hermanides R, Bergmeijer T, de Vrey E, Heestermans T, Tjon Joe Gin M, Waalewijn R, Hofma S, den Hartog F, Jukema W, von Birgelen C, Voskuil M, Kelder J, Deneer V, Ten Berg J. Gimbel M, et al. Lancet. 2020 Apr 25;395(10233):1374-1381. doi: 10.1016/S0140-6736(20)30325-1. Lancet. 2020. PMID: 32334703 Clinical Trial.
95 results